Boost for AstraZeneca as breast cancer drug Lynparza gets green light from European regulators
AstraZeneca’s drug pipeline got a boost after European regulators approved one of its cancer treatments.
The pharmaceutical giant’s Lynparza drug has been approved by the European Commission to treat people suffering from a type of early-stage, high-risk breast cancer.
The approval followed data from a phase III clinical trial published last June that found Lynparza reduced the risk of death by 32 percent.
Approved: AstraZeneca’s Lynparza has been approved by the European Commission for the treatment of patients suffering from a type of early-stage, high-risk breast cancer
The drug was approved for use in breast cancer patients in the US in March.
“Today’s approval marks a new era of care in Europe for patients with hereditary breast cancer,” said Andrew Tutt, a professor of oncology at the Institute of Cancer Research in London, who led the clinical trial.
In Britain, about 11,500 die from breast cancer each year, according to Cancer Research UK.
Approval in the EU will lead to a £62 million payment to AstraZeneca from US pharmaceutical group Merck & Co, with whom it partnered to develop the treatment.
AstraZeneca shares rose 0.5 percent, or 58p, to 10720p after the news, further cementing its position as the most valuable company in the London stock market, worth around £165 billion.
The EU approval presents another opportunity for the company’s cancer drug pipeline after its £1.1 billion purchase from US company TeneoTwo last month, giving it access to TNB-486, an early-stage experimental treatment for a form of non-Hodgkin’s lymphoma, a type of blood cancer that can lead to tumors.
Enhertu, another cancer drug it co-developed with Japan’s Daiichi Sankyo, is already approved for use in the EU and the US for certain types of breast cancer.